What are the uses for Aldactone (spironolactone) in patients with a history of cardiovascular disease or those at risk for developing it?

Uses for Aldactone (Spironolactone) in Cardiovascular Disease

Aldactone (spironolactone) is FDA-approved and strongly recommended for NYHA Class III-IV heart failure with reduced ejection fraction to increase survival, manage edema, and reduce hospitalizations, and as add-on therapy for resistant hypertension. 1

Primary Cardiovascular Indications

Heart Failure with Reduced Ejection Fraction (HFrEF)

Spironolactone should be added to ACE inhibitors and beta-blockers in patients with severe left ventricular dysfunction (NYHA class III-IV) to increase survival. 2, 1

• The landmark RALES trial demonstrated that spironolactone 25-50 mg daily reduced all-cause mortality by 30% and heart failure hospitalizations by 35% in patients with NYHA class III-IV heart failure and ejection fraction ≤35%. 2, 1
• This mortality benefit translates to a number needed to treat of only 9 patients for 2 years to prevent one death. 1
• The survival benefit occurred at low doses (mean 26 mg daily), below those needed for significant diuretic effects, indicating that aldosterone antagonism itself—not just diuresis—provides the protective effect. 3, 1
• Spironolactone reduces both progressive heart failure deaths and sudden cardiac death. 3

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

• In patients with LVEF 41-49%, post hoc analysis of the TOPCAT trial showed spironolactone reduced the composite endpoint of cardiovascular death, heart failure hospitalization, or resuscitated sudden death, primarily driven by reduced cardiovascular mortality. 2
• Spironolactone is particularly preferred in HFmrEF patients with poorly controlled hypertension given its established blood pressure-lowering effects. 2

Resistant Hypertension

• Spironolactone is FDA-approved as add-on therapy for hypertension not adequately controlled on other agents, with doses of 25-50 mg daily providing significant additional blood pressure reduction when added to multidrug regimens. 3, 1
• Blood pressure reduction with spironolactone decreases the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1

Mechanism of Cardiovascular Protection

• Spironolactone acts as a competitive antagonist at the mineralocorticoid receptor, blocking aldosterone's effects on sodium retention and potassium wasting. 3
• Beyond diuresis, aldosterone promotes vascular and myocardial fibrosis, potassium and magnesium depletion, sympathetic activation, and baroreceptor dysfunction—all blocked by spironolactone. 3
• ACE inhibitors and ARBs provide only short-term aldosterone suppression that is not sustained during long-term treatment, creating a therapeutic gap that spironolactone fills. 3

Additional FDA-Approved Indications

• Edema associated with hepatic cirrhosis when unresponsive to fluid and sodium restriction. 1
• Edema associated with nephrotic syndrome when other measures produce inadequate response. 1
• Primary hyperaldosteronism for short-term preoperative treatment or long-term maintenance in non-surgical candidates. 1
• Spironolactone is particularly useful for treating edema when other diuretics have caused hypokalemia. 1

Critical Monitoring Requirements

Careful monitoring for hyperkalemia is mandatory, with potassium and creatinine checks at baseline, 3 days, 1 week, then monthly for 3 months, then every 3-6 months. 3

• Patients with baseline serum creatinine >2.5 mg/dL or serum potassium >5.0 mEq/L should be excluded from therapy. 1
• Therapy should be limited to patients with serum creatinine ≤2.5 mg/dL to reduce hyperkalemia risk. 3
• Spironolactone should be stopped immediately if potassium exceeds 5.5 mEq/L. 4

Important Caveats and Side Effects

• Gynecomastia occurs in approximately 10% of men due to non-selective steroid receptor effects, which may limit long-term use. 3, 4
• Decreased libido occurs in more than 10% of patients through anti-androgenic properties, affecting both men (decreased testosterone production, impotence) and women (menstrual irregularities, decreased arousal). 4, 5
• Alternative aldosterone antagonists (eplerenone) or diuretics (hydrochlorothiazide, chlorthalidone) should be considered in patients with pre-existing sexual dysfunction, as these lack anti-androgenic effects. 4, 5
• Patients should be stable before initiation; use with caution in recently decompensated patients and only initiate in hospital in these cases. 2

Dosing Strategy

• Start with 25 mg once daily. 2, 1
• Patients intolerant of initial dosing may decrease to 25 mg every other day. 1
• Patients tolerant at 8 weeks may increase to 50 mg daily based on clinical response. 1
• Target dose is 25-50 mg daily based on landmark trials. 2